Advanced search
Publication Cover
Xenobiotica
the fate of foreign compounds in biological systems
Volume 9, 1979 - Issue 7
Submit an article Journal homepage
56
Views
62
CrossRef citations to date
0
Altmetric
Original Article

Interindividual and interspecies variation in the metabolism of the hallucinogen 4-methoxyamphetamine

I. Kitchen Department of Pharmacology, Basic Medical Sciences Group, Chelsea College, University of London, London, SW3 6LX, UK
,
J. Tremblay Faculté de Pharmacie, Université de Montréal, Montréal, Canada
,
J. André Department of Biochemistry, Michigan State University, East Lansing, Michigan, 48823, USA
,
L. G. Dring L.E.R.S.—Synthélabo, Animal Pharmacokinetics Group, Department of Clinical Research, 58 rue de la Glacière, 75621, Paris, Cedex, 13, France
,
J. R. Idle Departments of Biochemistry and of Biochemical and Experimental Pharmacology, St Mary's Hospital Medical School, London, W2 1PG, UK
,
R. L. Smith Departments of Biochemistry and of Biochemical and Experimental Pharmacology, St Mary's Hospital Medical School, London, W2 1PG, UK
&
R. T. Williams Departments of Biochemistry and of Biochemical and Experimental Pharmacology, St Mary's Hospital Medical School, London, W2 1PG, UK
 show all
Pages 397-404 | Received 02 Oct 1978, Published online: 30 Sep 2009

Citations (62)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (12)

Kevin A. Ford, Gregory Ryslik, Jasleen Sodhi, Jason Halladay, Dolo Diaz, Donna Dambach & Melisa Masuda. (2015) Computational predictions of the site of metabolism of cytochrome P450 2D6 substrates: comparative analysis, molecular docking, bioactivation and toxicological implications. Drug Metabolism Reviews 47:3, pages 291-319.
Read now
Yael Lurie, Asher Gopher, Ophir Lavon, Shlomo Almog, Liron Sulimani & Yedidia Bentur. (2012) Severe paramethoxymethamphetamine (PMMA) and paramethoxyamphetamine (PMA) outbreak in Israel. Clinical Toxicology 50:1, pages 39-43.
Read now
Slobodan Rendic. (2002) Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metabolism Reviews 34:1-2, pages 83-448.
Read now
Lars W. Wormhoudt, Jan N. M. Commandeur & Nico P. E. Vermeulen. (1999) Genetic Polymorphisms of Human N-Acetyltransferase, Cytochrome P450, Glutathione-S-Transferase, and Epoxide Hydrolase Enzymes: Relevance to Xenobiotic Metabolism and Toxicity. Critical Reviews in Toxicology 29:1, pages 59-124.
Read now
MIMI V. BACH, R. T. COUTTS & G. B. BAKER. (1999) Involvement of CYP2D6 in the in vitro metabolism of amphetamine, two N-alkylamphetamines and their 4-methoxylated derivatives. Xenobiotica 29:7, pages 719-732.
Read now
Slobodan Rendic & Frederick J. Di Carlo. (1997) Human Cytochrome P450 Enzymes: A Status Report Summarizing Their Reactions, Substrates, Inducers, and Inhibitors. Drug Metabolism Reviews 29:1-2, pages 413-580.
Read now
B. C. Foster, D. L. Litster & B. A. Lodge. (1991) Biotransformation of 2-, 3-, and 4-methoxy-amphetamines by Cunninghamella echinulata. Xenobiotica 21:10, pages 1337-1346.
Read now
B. C. Foster, L. M. Nantais, D. L. Wilson, A. W. By, J. Zamecnik & B. A. Lodge. (1990) Fungal metabolism of 4-substituted amphetamines. Xenobiotica 20:6, pages 583-590.
Read now
A. Küpfer, B. Schmid & G. Pfaff. (1986) Pharmacogenetics of dextromethorphan O-demethylation in man. Xenobiotica 16:5, pages 421-433.
Read now
R. L. Smith. (1986) Introduction. Xenobiotica 16:5, pages 361-365.
Read now
K. K. Midha, E. M. Hawes, J. K. Cooper, J. W. Hubbard, K. Bailey & I. J. McGilveray. (1983) The identification of two new urinary metabolites of fenfluramine in man. Xenobiotica 13:1, pages 31-38.
Read now
K. K. Midha, J. K. Cooper, K. Bailey & J. W. Hubbard. (1981) The metabolism of 3-methoxyamphetamine in dog, monkey and man. Xenobiotica 11:2, pages 137-146.
Read now

Articles from other publishers (50)

Jeff Lapoint & Katherine L. Welker. 2022. Novel Psychoactive Substances. Novel Psychoactive Substances 247 278 .
Raj B. Patel & Samuel H. Yalkowsky. (2018) A rule of unity for human intestinal absorption 3: Application to pharmaceuticals. Biopharmaceutics & Drug Disposition 39:2, pages 67-74.
Crossref
Elli Tyrkkö, Mikael Andersson & Robert Kronstrand. (2016) The Toxicology of New Psychoactive Substances. Therapeutic Drug Monitoring 38:2, pages 190-216.
Crossref
Foon Yin Lai, Claudio Erratico, Juliet Kinyua, Jochen F. Mueller, Adrian Covaci & Alexander L.N. van Nuijs. (2015) Liquid chromatography-quadrupole time-of-flight mass spectrometry for screening in vitro drug metabolites in humans: investigation on seven phenethylamine-based designer drugs. Journal of Pharmaceutical and Biomedical Analysis 114, pages 355-375.
Crossref
Kei Zaitsu, Munehiro Katagi, Hitoshi Tsuchihashi & Akira Ishii. (2013) Recently abused synthetic cathinones, α-pyrrolidinophenone derivatives: a review of their pharmacology, acute toxicity, and metabolism. Forensic Toxicology 32:1, pages 1-8.
Crossref
Jeff Lapoint, Paul I. Dargan & Robert S. Hoffman. 2013. Novel Psychoactive Substances. Novel Psychoactive Substances 161 178 .
Markus R. Meyer & Hans H. Maurer. 2012. Metabolism of Drugs and Other Xenobiotics. Metabolism of Drugs and Other Xenobiotics 429 463 .
Usman Khan & Jim A. Nicell. (2012) Sewer epidemiology mass balances for assessing the illicit use of methamphetamine, amphetamine and tetrahydrocannabinol. Science of The Total Environment 421-422, pages 144-162.
Crossref
Donald G. BarcelouxBrandon Wills & Timothy Erickson. 2012. Medical Toxicology of Drug Abuse. Medical Toxicology of Drug Abuse 156 192 .
M.-H. Ghysel-Laporte, P. Sibille & N. Milan. 2012. Traité De Toxicologie Médico-judiciaire. Traité De Toxicologie Médico-judiciaire 455 505 .
S G AL-DABBAGH, J R IDLE & R L SMITH. (1981) Animal modelling of human polymorphic drug oxidation—the metabolism of debrisoquine and phenacetin in rat inbred strains. Journal of Pharmacy and Pharmacology 33:1, pages 161-164.
Crossref
Laurie A. Zawertailo, Rachel F. Tyndale, U. Busto & Edward M. Sellers. (2009) Effect of metabolic blockade on the psychoactive effects of dextromethorphan. Human Psychopharmacology: Clinical and Experimental 25:1, pages 71-79.
Crossref
Kei Zaitsu, Munehiro Katagi, Tooru Kamata, Hiroe Kamata, Noriaki Shima, Hitoshi Tsuchihashi, Takeshi Hayashi, Hisanaga Kuroki & Ryoji Matoba. (2008) Determination of a newly encountered designer drug “p-methoxyethylamphetamine” and its metabolites in human urine and blood. Forensic Science International 177:1, pages 77-84.
Crossref
Paul D. Callaghan, W. Anthony Owens, Martin A. Javors, Teresa A. Sanchez, David J. Jones, Rodney J. Irvine & Lynette C. Daws. (2007) In vivo analysis of serotonin clearance in rat hippocampus reveals that repeated administration of p-methoxyamphetamine (PMA), but not 3,4-methylenedioxymethamphetamine (MDMA), leads to long-lasting deficits in serotonin transporter function. Journal of Neurochemistry 100:3, pages 617-627.
Crossref
Paul D. Callaghan, Kirsten Farrand, Abdallah Salem, Patrick Hughes, Lynette C. Daws & Rodney J. Irvine. (2006) Repeated administration of the substituted amphetamine p-methoxyamphetamine produces reductions in cortical 5-HT transporter binding but not 5-HT content, unlike 3,4-methylenedioxyamethamphetamine. European Journal of Pharmacology 546:1-3, pages 74-81.
Crossref
Hans H. Maurer, Christoph Sauer & Denis S. Theobald. (2006) Toxicokinetics of Drugs of Abuse: Current Knowledge of the Isoenzymes Involved in the Human Metabolism of Tetrahydrocannabinol, Cocaine, Heroin, Morphine, and Codeine. Therapeutic Drug Monitoring 28:3, pages 447-453.
Crossref
Rafael de la Torre, Mag?? Farr??M??nica Navarro, Roberta Pacifici, Piergiorgio Zuccaro & Simona Pichini. (2004) Clinical Pharmacokinetics of Amfetamine and Related Substances. Clinical Pharmacokinetics 43:3, pages 157-185.
Crossref
Wenjiang Zhang, Yamini Ramamoorthy, Rachel F. Tyndale & Edward M. Sellers. (2003) INTERACTION OF BUPRENORPHINE AND ITS METABOLITE NORBUPRENORPHINE WITH CYTOCHROMES P450 IN VITRO. Drug Metabolism and Disposition 31:6, pages 768-772.
Crossref
Munehiro KatagiHitoshi Tsuchihashi. (2002) Update on Clandestine Amphetamines and Their Analogues Recently Seen in Japan.. Journal of Health Science 48:1, pages 14-21.
Crossref
Yamini Ramamoorthy, Rachel F. Tyndale & Edward M. Sellers. (2001) Cytochrome P450 2D6.1 and cytochrome P450 2D6.10 differ in catalytic activity for multiple substrates. Pharmacogenetics 11:6, pages 477-487.
Crossref
Ah-Ng Tony Kong, Rong Yu, Chi Chen, Sandhya Mandlekar & Thomas Primiano. (2000) Signal transduction events elicited by natural products: Role of MAPK and caspase pathways in homeostatic response and induction of apoptosis. Archives of Pharmacal Research 23:1, pages 1-16.
Crossref
EDWARD M. SELLERS & RACHEL F. TYNDALE. (2006) Mimicking Gene Defects to Treat Drug Dependence. Annals of the New York Academy of Sciences 909:1, pages 233-246.
Crossref
Snjezana Lelas, Sandra Wegert, S.Victoria Otton, Edward M. Sellers & Charles P. France. (1999) Inhibitors of cytochrome P450 differentially modify discriminative-stimulus and antinociceptive effects of hydrocodone and hydromorphone in rhesus monkeys. Drug and Alcohol Dependence 54:3, pages 239-249.
Crossref
Ann Daly. 1999. Handbook of Drug Metabolism. Handbook of Drug Metabolism 175 202 .
Dafang Wu, S.Victoria Otton, Tadanobu Inaba, Werner Kalow & Edward M. Sellers. (1997) Interactions of amphetamine analogs with human liver CYP2D6. Biochemical Pharmacology 53:11, pages 1605-1612.
Crossref
Heyo K. Kroemer & Michel Eichelbaum. (1995) “It's the genes, stupid” Molecular bases and clinical consequences of genetic cytochrome P450 2D6 polymorphism. Life Sciences 56:26, pages 2285-2298.
Crossref
F. Peter Guengerich. 1995. Cytochrome P450. Cytochrome P450 473 535 .
Micheal Y.L. Law & David E. Moody. (1994) Urinary excretion of amphetamine and 4′-hydroxyamphetamine by sprague dawley and dark agouti rats. Life Sciences 54:15, pages 1073-1079.
Crossref
H. K. Kroemer, G. Mikus & M. Eichelbaum. 1994. Pharmacokinetics of Drugs. Pharmacokinetics of Drugs 265 288 .
Brian C. Foster, Dionne L. Litster, Harpal S. Buttar, Brian Dawson & Jiri Zamecnik. (2006) Biotransformation and urinary excretion of 4‐substituted amphetamines in pregnant mice. Biopharmaceutics & Drug Disposition 14:8, pages 709-719.
Crossref
D. Wu, SV Otton, BA Sproule, U. Busto, T. Inaba, W. Kalow & EM Sellers. (2012) Inhibition of human cytochrome P450 2D6 (CYP2D6) by methadone.. British Journal of Clinical Pharmacology 35:1, pages 30-34.
Crossref
Ann K. Daly, Suzanne Cholerton, Wendy Gregory & Jeffrey R. Idle. (1993) Metabolic polymorphisms. Pharmacology & Therapeutics 57:2-3, pages 129-160.
Crossref
P. Lledó. (2012) Variations in Drug Metabolism Due to Genetic Polymorphism. Drug Investigation 5:1, pages 19-34.
Crossref
EDWARD M. SELLERS, S. VICTORIA OTTON & USOA E. BUSTO. (2010) Drug metabolism and interactions in abuse liability assessment. British Journal of Addiction 86:12, pages 1607-1614.
Crossref
Luc Daumas, Jean-François Sabot, Eliane Vermeulen, Pascale Clapot, Françoise Allegre, Henri Pinatel, Michel Boucherat & Bernard Francois. (1991) Determination of debrisoquine and metabolites in human urine by gas chromatography—mass spectrometry. Journal of Chromatography B: Biomedical Sciences and Applications 570:1, pages 89-97.
Crossref
G. Alván. (2009) Clinical consequences of polymorphic drug oxidation. Fundamental & Clinical Pharmacology 5:3, pages 209-228.
Crossref
M. Eichelbaum & A.S. Gross. (1990) The genetic polymorphism of debrisoquine/sparteine metabolism — Clinical aspects. Pharmacology & Therapeutics 46:3, pages 377-394.
Crossref
K. Br�sen & L. F. Gram. (1989) Clinical significance of the sparteine/debrisoquine oxidation polymorphism. European Journal of Clinical Pharmacology 36:6, pages 537-547.
Crossref
Pierre Dayer, Thomas Kronbach, Michel Eichelbaum & Urs A. Meyer. (1987) Enzymatic basis of the debrisoquine/sparteine-type genetic polymorphism of drug oxidation. Biochemical Pharmacology 36:23, pages 4145-4152.
Crossref
Evelyne Jacqz, Stephen D. Hall & Robert A. Branch. (1986) Genetically determined polymorphisms in drug oxidation. Hepatology 6:5, pages 1020-1032.
Crossref
RV Lewis, MS Lennard, PR Jackson, GT Tucker, LE Ramsay & HF Woods. (2012) Timolol and atenolol: relationships between oxidation phenotype, pharmacokinetics and pharmacodynamics.. British Journal of Clinical Pharmacology 19:3, pages 329-333.
Crossref
JH Silas, MS Lennard, GT Tucker, LE Ramsay & HF Woods. (2012) Polymorphic metabolism of beta‐adrenoceptor antagonists.. British Journal of Clinical Pharmacology 17:S1.
Crossref
HW Devonshire, I. Kong, M. Cooper, TP Sloan, J.R. Idle & RL Smith. (2012) The contribution of genetically determined oxidation status to inter‐ individual variation in phenacetin disposition.. British Journal of Clinical Pharmacology 16:2, pages 157-166.
Crossref
. (1983) Oxidation Phenotype and Beta-Blockers. New England Journal of Medicine 308:16, pages 964-966.
Crossref
P. Dayer, L. Balant, A. K�pfer, F. Courvoisier & J. Fabre. (1983) Contribution of the genetic status of oxidative metabolism to variability in the plasma concentrations of beta-adrenoceptor blocking agents. European Journal of Clinical Pharmacology 24:6, pages 797-799.
Crossref
BK Park. (2012) Assessment of the drug metabolism capacity of the liver.. British Journal of Clinical Pharmacology 14:5, pages 631-651.
Crossref
GC Kahn, AR Boobis, S Murray, MJ Brodie & DS Davies. (2012) Assay and characterisation of debrisoquine 4‐hydroxylase activity of microsomal fractions of human liver.. British Journal of Clinical Pharmacology 13:5, pages 637-645.
Crossref
Daniel B Menzel. (1980) Carcinogens and Other Toxic Hazards: How Accurate Are Animal Studies?. Pediatric Annals 9:12, pages 48-56.
Crossref
D A Evans, A Mahgoub, T P Sloan, J R Idle & R L Smith. (1980) A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population.. Journal of Medical Genetics 17:2, pages 102-105.
Crossref
J.C. Ritchie, T.P. Sloan, J.R. Idle & R.L. Smith. 1980. Ciba Foundation Symposium 76 - Environmental Chemicals, Enzyme Function and Human Disease. Ciba Foundation Symposium 76 - Environmental Chemicals, Enzyme Function and Human Disease 219 244 .

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.